MAP2K7 and metastatic melanoma: New effective molecular-targeted agents (1) including combination serine-threonine protein kinase BRAF inhibitor and mitogen-activated protein kinase kinase (MEK) inhibitor (BRAF/MEK inhibitor) therapy have improved overall survival (OS) and progression-free survival (PFS) of patients with metastatic melanoma with BRAFV600E/K mutations (2), (3), (4).